Suppr超能文献

预防骨折的药物干预的骨密度阈值。

Bone mineral density thresholds for pharmacological intervention to prevent fractures.

作者信息

Siris Ethel S, Chen Ya-Ting, Abbott Thomas A, Barrett-Connor Elizabeth, Miller Paul D, Wehren Lois E, Berger Marc L

机构信息

Metabolic Bone Disease Program, Toni Stabile Osteoporosis Center, Columbia-Presbyterian Medical Center, 180 Fort Washington Avenue, New York, NY 10032-3784, USA.

出版信息

Arch Intern Med. 2004 May 24;164(10):1108-12. doi: 10.1001/archinte.164.10.1108.

Abstract

BACKGROUND

Treatment intervention thresholds for prevention of osteoporotic fractures can be derived from reports from the World Health Organization (diagnostic criteria) and National Osteoporosis Foundation (treatment criteria). It is not known how well these thresholds work to identify women who will fracture and are therefore candidates for treatment interventions. We used data from the National Osteoporosis Risk Assessment (NORA) to examine the effect of different treatment thresholds on fracture incidence and numbers of women with fractures within the year following bone mineral density measurement.

METHODS

The study comprised 149 524 white postmenopausal women aged 50 to 104 years (mean age, 64.5 years). At baseline, bone mineral density was assessed by peripheral bone densitometry at the heel, finger, or forearm. New fractures during the next 12 months were self-reported.

RESULTS

New fractures were reported by 2259 women, including 393 hip fractures; only 6.4% had baseline T scores of -2.5 or less (World Health Organization definition for osteoporosis). Although fracture rates were highest in these women, they experienced only 18% of the osteoporotic fractures and 26% of the hip fractures. By National Osteoporosis Foundation treatment guidelines, 22.6% of the women had T scores of 2.0 or less, or -1.5 or less with 1 or more clinical risk factors. Fracture rates were lower, but 45% of osteoporotic fractures and 53% of hip fractures occurred in these women.

CONCLUSIONS

Using peripheral measurement devices, 82% of postmenopausal women with fractures had T scores better than -2.5. A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures.

摘要

背景

预防骨质疏松性骨折的治疗干预阈值可源自世界卫生组织的报告(诊断标准)和美国国家骨质疏松基金会的报告(治疗标准)。目前尚不清楚这些阈值在识别可能发生骨折并因此适合接受治疗干预的女性方面效果如何。我们利用国家骨质疏松风险评估(NORA)的数据,研究了不同治疗阈值对骨密度测量后一年内骨折发生率以及骨折女性人数的影响。

方法

该研究纳入了149524名年龄在50至104岁之间的白人绝经后女性(平均年龄64.5岁)。基线时,通过足跟、手指或前臂的外周骨密度测量法评估骨密度。接下来12个月内的新发骨折情况由患者自行报告。

结果

2259名女性报告发生了新发骨折,其中包括393例髋部骨折;只有6.4%的女性基线T值≤ -2.5(世界卫生组织对骨质疏松症的定义)。尽管这些女性的骨折率最高,但她们仅经历了18%的骨质疏松性骨折和26%的髋部骨折。根据美国国家骨质疏松基金会的治疗指南,22.6%的女性T值≤ -2.0,或T值≤ -1.5且伴有1个或更多临床风险因素。这些女性的骨折率较低,但发生了45%的骨质疏松性骨折和53%的髋部骨折。

结论

使用外周测量设备时,82%发生骨折的绝经后女性T值优于 -2.5。降低总体骨折发生率的策略可能需要改变生活方式,并针对性地努力为骨量较低但未来骨折风险仍较高的女性识别和制定治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验